International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(9), P. 4264 - 4264
Published: April 30, 2025
Cardiovascular diseases (CVDs), including heart failure (HF), hypertension, myocardial infarction (MI), and atherosclerosis, are increasingly linked to gut microbiota dysbiosis its metabolic byproducts. HF, affecting over 64 million individuals globally, is associated with systemic inflammation barrier dysfunction, exacerbating disease progression. Similarly, hypertension MI correlate reduced microbial diversity an abundance of pro-inflammatory bacteria, contributing vascular increased cardiovascular risk. Atherosclerosis also influenced by dysbiosis, key metabolites such as trimethylamine-N-oxide (TMAO) short-chain fatty acids (SCFAs) playing crucial roles in pathogenesis. Emerging evidence highlights the therapeutic potential natural compounds, flavonoids, omega-3 acids, resveratrol, curcumin, marine-derived bioactives, which modulate confer cardioprotective effects. These insights underscore a critical regulator health, suggesting that targeting may offer novel preventive strategies. Further research needed elucidate underlying mechanisms optimize microbiome-based interventions for improved outcomes.
Language: Английский